期刊文献+

肝复乐胶囊治疗慢性乙型肝炎、肝硬化临床疗效观察 被引量:8

Efficacy of Ganfule Jiaonang for chronic hepatitis B
暂未订购
导出
摘要 目的观察中药复方制剂肝复乐胶囊治疗慢性乙型肝炎、肝硬化患者的疗效。方法慢性乙型肝炎、肝硬化患者102例,分为3组:对照组A(34例)采用常规保肝治疗加安慰剂胶囊,对照组B(34例)采用常规保肝治疗加肝友胶囊,治疗组(34例)采用常规保肝治疗加肝复乐胶囊,疗程均为8周。治疗前后测定血清中透明质酸(HA)、IV型胶原(CIV)、层粘连蛋白(LN)。结果治疗组用药后HA为(87.3±36.6)μg.L-1,CIV为(5.2±0.7)μg.mL-1,LN为(373.2±49.6)μg.L-1,与对照组A比有显著性差异(P<0.05)。肝功能复常情况治疗组ALT为(35.9±3.3)U.L-1,AST为(35.8±5.4)U.L-1,Tbil为(16.6±4.2)μmol.L-1;治疗组第8周后的主要症状改善率(100.0%)显著高于对照组A(82.4%)(P<0.05),略高于对照组B(91.2%)(P>0.05)。结论肝复乐胶囊具有减轻肝细胞炎症及抗肝纤维化的作用,可以作为慢性乙型肝炎、肝硬化综合治疗用药选择。 Objective To observe the efficacy of Ganfule Jiaonang,a Chinese traditional medicine compound preparation,for chronic hepatitis B and cirrhosis treatment.Methods A total of 102 patients who had chronic hepatitis B and cirrhosis were divided into 3 groups.Patients(n=34) in the control group A were given routine medical therapy and placebo Jiaonang;patients(n=34) in the control group B were given routine medical therapy and Ganyou capsules(another Chinese traditional medicine compound preparation);and patients(n=34) in the treatment group were given routine medical therapy and Ganfule Jiaonang.The usage for Ganfule Jiaonang was 6 pellets at a time,3 times a day for 8 weeks.Some serum indicators for hepatic functions such as alanine aminotrabsferease(ALT),hyaluronic(HA),collagen type IV(CIV) and lamini(LN) were tested before and after the treatment.Results In the treatment group,the serum HA concentration was(87.3 ±36.6) μg·L-1,the serum CIV concentration was(5.2 ±0.7)μg·mL-1,and the serum LN concentration was(373.2±49.6)μg·L-1 after the therapy(compared with the control group A and B,all P values〈0.05).In the control group A and B,no changes were observed for HA,CIV and LN before and after the therapy(all P values〈0.05).With normal liver function,the serum ALT,AST and Tbil concentrations were(35.9±3.3)U·L-1,(35.8±5.4),and(16.6±4.2) μmol·L-1.Eight weeks after the treatment,the rate of recovery in the treatment group was 100.0%,compared with the control group A(82.4%,P〈0.05)and the control group B(91.2%,P〉0.05).Conclusion Ganfule Jiaonang can alleviate liver inflammation and resist liver fibrosis,indicating that it is effective for chronic hepatitis B and cirrhosis treatment.
出处 《中南药学》 CAS 2010年第11期872-875,共4页 Central South Pharmacy
关键词 肝复乐胶囊 乙型肝炎 肝硬化 临床疗效 Ganfule Jiaonang hepatitis B cirrhosis clinical efficacy
  • 相关文献

参考文献9

二级参考文献29

共引文献15641

同被引文献64

  • 1刘嵘,王建华,周康荣,严福华,颜志平.碘油栓塞后临床长期稳定肝癌病灶的MRI研究[J].放射学实践,2006,21(9):928-932. 被引量:5
  • 2Liver Disease Committee,Chinese Association of Integrative Medicine..肝纤维化中西医结合诊疗指南[J].中华肝脏病杂志,2006,14(11):866-870. 被引量:271
  • 3张传光,吴新奎,荆才玉,李凤云.肝动脉栓塞化疗联合口服肝复乐治疗中晚期原发性肝癌56例临床观察[J].实用癌症杂志,2007,22(5):499-500. 被引量:5
  • 4McMahon BJ. Implementing evidenced-based practice guidelines for the management of chronic hepatitis B virus infection[ J]. Am Med, 2008, 121(12suppl) : s45-52.
  • 5Lim SG, Aung MO, Mak B, et al. Clinical outcomes of Lamivudi- ne-adefovir therapy in chronic hepatitis B cirrhosis[ J ]. Clin Gastroenterol, 2011, 45 (9) : 818 - 823.
  • 6周德江,何胜,翁敏.口服肝复乐联合经皮肝动脉栓塞化疗治疗中晚期原发性肝癌42例临床观察[J].医药前沿,2011 ,1(24): 10-11 .
  • 7Ferrari F S,Stella A,Pasquinucci P,et al.Treatment of small hepatocellular carcinoma:a comparison of techniques and longterm results[J].Eur J Gastroenterol Hepatol,2006,18(6):659-672.
  • 8Adachi E,Maeda T,Matsumata T,et al.Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma[J].Gastroenterology,1995,108(3):768-775.
  • 9Bronowicki JP,Boudjema K,Chone L,et al.Comparison of resection,liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma[J].J Hepatol,1996,24(3):293-300.
  • 10Llovet J M,Real M I,Montaa X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部